HDAC1: a promising target for cancer treatment: insights from a thorough analysis of tumor functions
Authors:
Open Access
- 1 October 2024
- journal article
- research article
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (10) , 5300-5315
Abstract
Background: Many significant findings from recent studies have revealed the significance of histone deacetylase 1 (HDAC1) in the development of tumors and its strong association with tumor prognosis; these studies have mainly focused on one single cancer such as in lung cancer, breast cancer, and hepatocellular carcinoma (HCC). To date, there has been no comprehensive analysis and pan-analysis conducted from the overall perspective of cancer across all types. Hence, we analyzed public databases, conducted tube formation assay, and immunohistochemistry (IHC) staining of HDAC1 on six kinds of clinical samples to explore the prognostic and oncogenic effects of HDAC1 on 33 tumors for the first time. There currently remains a lack of efficient testing methods, therapies, and diagnostic and prognostic markers of tumor formation and development in different tumors. Methods: Our initial objective was to investigate the possible cancer-causing functions of HDAC1 in 33 different types of tumors by utilizing The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, and many different online websites, such as Tumor IMmune Estimation Resource 2 (TIMER2), Gene Expression Profiling Interactive Analysis 2 (GEPIA2), Genotype Tissue Expression (GTEx) database, Clinical Proteomic Tumor Analysis Consortium (CPTAC) dataset, and University of ALabama at Brimingham CANcer data analysis portal (UALCAN) tool, and so on. We even used small interfering RNA (siRNA) to knock down HDAC2 in HCC cell lines. IHC of HDAC1 was performed. Results: HDAC1 exhibited high expression in numerous tumors, and strong correlations were observed between the messenger RNA (mRNA) levels of HDAC1 and the prognosis of individuals diagnosed with tumors. Human umbilical vein endothelial cells (HUVECs) tube formation and migration were significantly inhibited by conditioned media from HCC cells treated with siRNA of HDAC1. Several types of cancer have been found to exhibit elevated levels of phosphorylation at S421. Furthermore, as in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), and kidney renal papillary cell carcinoma (KIRP), HDAC1 expression was found to be correlated with inflammatory cell infiltration. Conclusions: The levels of HDAC1 are expected to adapt to clinical adjuvant targeted therapy in most types of solid cancer.Keywords
This publication has 33 references indexed in Scilit:
- SnapShot: TCGA-Analyzed TumorsCell, 2018
- Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21Waf1/Cip1 and p19INK4d upregulation in hepatocellular carcinomaCell Proliferation, 2018
- The Role of Immune Escape and Immune Cell Infiltration in Breast CancerBreast Care, 2018
- HDAC1 and HDAC2 in mouse oocytes and preimplantation embryos: Specificity versus compensationCell Death & Differentiation, 2016
- The Gene Expression Omnibus Database2016
- Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledgeContemporary Oncology, 2015
- Loss of histone deacetylases 1 and 2 in hepatocytes impairs murine liver regeneration through Ki67 depletionHepatology, 2013
- Type‐specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E‐cadherinInternational Journal of Cancer, 2010
- Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control2010
- Histone Deacetylase 1 Phosphorylation Promotes Enzymatic Activity and Complex FormationJournal of Biological Chemistry, 2001